Background: There is conflicting evidence on specific reverse transcriptase inhibitors to which the N348I mutation in the connection domain of HIV type-1 reverse transcriptase confers resistance. Here, we examined associations between the emergence of N348I and antiretroviral history in a large clinical database. Methods: We analysed 5,353 resistance tests (that were sequenced beyond codon 348) among 2,266 antiretroviral-experienced patients. Associations between N348I and individual antiretroviral drug exposure were estimated using a matched case-control approach. Cases were defined as the first resistance test where N348I was detected; for each case, the 10 closest (in calendar time) N348N tests were selected as controls. Odds ratios (ORs) adjusted for effects of all other drugs were estimated by conditional logistic regression. 
There are two classes of drugs that target the HIV type-1 (HIV-1) reverse transcriptase (RT). These drugs act as chain terminators and prevent the addition of natural nucleotides (nucleoside reverse transcriptase inhibitors [NRTIs] ) or bind to the RT and alter the active site, thereby preventing DNA synthesis (nonnucleoside reverse transcriptase inhibitors [NNRTIs] ). Most NRTI and NNRTI mutations are clustered around the polymerase active site, corresponding to the first 250-300 N-terminal amino acids; however, RT also includes the connection domain and ribonuclease H (RNase H) domain in the C-terminal region. Until recently, it was not suspected that these domains played any role in resistance to NRTIs or NNRTIs in view of their distance from the active drug binding sites; however, this notion was challenged by an analysis of a large sequence database that found that several connection domain mutations were present at a much higher frequency (approximately 20-fold) in samples with classical resistance mutations compared with samples without such mutations [1] . Similar findings were reported from another database in an analysis of subtype B viruses in 
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relation to thymidine analogue mutations (TAMs) and NNRTI-associated mutations specifically [2] .
These discoveries stimulated a number of groups to undertake in vitro research on the connection domain and RNase H domain mutations, primarily examining the mechanism of resistance to zidovudine; this appears to occur through connection and RNase H mutations that compromise RNase H cleavage and provide more time for zidovudine excision to occur [3] [4] [5] . The N348I connection domain mutation has also been shown to confer reduced susceptibility to nevirapine [6] [7] [8] [9] [10] . The mechanism of resistance has not been fully elucidated, although it might be relevant that codon 348 is close to both the NNRTI binding pocket and to the base of the thumb domain [4, 7, 11, 12] .
Drugs other than zidovudine and nevirapine have also been assessed in vitro, but results have been inconsistent, possibly because of variation in experimental techniques and the small number of specimens typically tested. Furthermore, in vitro studies do not fully capture the clinical complexity of combination therapy and the possibility of drug interactions on mutational pathways. There is, therefore, a need to additionally study the mutations that emerge clinically and to relate these to the antiretroviral treatment experience of individual patients; however, such research has been limited by the fact that HIV-1 sequence data from routine drug resistance testing only rarely extends to the connection and RNase H domains. In this paper, we present analyses of the N348I mutation, one of the most common and phenotypically important mutations in the connection domain [1, 3, 6] , with the aim of identifying the antiretroviral drugs that select for this mutation.
Methods
The analysis is based on pol gene sequences submitted to the UK HIV Drug Resistance Database, a central repository of genotypic resistance tests carried out as part of routine clinical care in the UK [13] . Data in the present analysis cover the period 1997-2006. The analysis was restricted to participants in the UK Collaborative HIV Cohort (UK CHIC) Study [14] (who therefore had a full antiretroviral treatment history), to participants who had been exposed to one or more reverse transcriptase inhibitors (RTIs) for a minimum of 30 days and to resistance tests that were sequenced up to or beyond codon 348 of the RT (excluding amino acid mixtures at codon 348 with the exception of N/I mixtures, which were interpreted as I). The latter criterion effectively limits the analysis to clinics that routinely use the genotypic test provided by Virco (Mechelen, Belgium), which sequences up to approximately position 400 in the RT.
In the main analysis, which examined associations between drug exposure and the N348I mutation, we used case-control methodology to account for multiple resistance tests per patient and a potential confounding effect of calendar time (there were large changes in prescribing practices over the period of the study). A case was defined as an individual in whom N348I was detected by the index resistance test, that is, the first resistance test that demonstrated this mutation. For each case we selected 10 control tests according to the following criteria: samples that demonstrated the wildtype amino acid (asparagine) at codon 348, samples that were closest in calendar time to the date of the index test, samples in which N348I had never previously been detected in that patient and samples that had at least one major International AIDS Society (IAS)-USA mutation [15] . The presence of wild-type virus implies that virological failure was probably caused by poor adherence [16] . The maximum gap between the case and matched control dates was 19 days. Odds ratios (ORs), both unadjusted and adjusted for the effects of other RTIs, were estimated by conditional logistic regression to take account of the matching of cases and controls. We also created four-level composite variables for certain pairs of drugs that generally select for the same set of mutations in the polymerase active site: exposure to neither drug, exposure to drug A only, exposure to drug B only and exposure to both drugs. This was performed for zidovudine and stavudine, and nevirapine and efavirenz; there was insufficient exposure to emtricitabine to assess its joint effects with lamuvidine.
Associations between N348I and major IAS-USA mutations [15] were measured in two ways (also using a case-control approach): considering the index test and all previous tests (including tests that did not sequence codon 348) and considering the index test only. The former analysis is the more relevant if using the presence of mutations as a marker for specific selective drug pressure, whereas the latter is more relevant for assessing mutational interactions.
Survival analysis was used to estimate the durability of the N348I mutation, with the time origin defined as the first test with N348I and the analysis limited to patients with at least one subsequent test that sequenced codon 348. The survivor function was modelled by restricted cubic spline regression on a log cumulative hazard scale, accounting for possible interval censoring of the event, that is, the re-emergence of wild-type virus [17] . Subtype was inferred using the REGA HIV subtyping algorithm [18] . No adjustment was made for multiple comparisons as, a priori, there was no plausible global null hypothesis, that is, the fact that N348I is frequently detected in antiretroviral therapy (ART)-experienced patients necessarily signifies selection pressure from one or more antiretroviral drugs [19] . All analyses were performed using STATA version 10.0 (StataCorp LP, College Station, TX, USA).
Results
Overall, the N348I mutation was detected in 20 (0.4%) of 4,635 samples from 3,676 patients who were ARTnaive at the time of sampling compared with 353 (6.6%) of 5,353 tests from 2,266 ART-experienced patients. Other substitutions at position 348 were observed infrequently (n=47 [0.5%]) regardless of ART exposure; these were predominantly threonine (T) substitutions (n=36 [0.4%]). N348I was the eleventh most common mutation found in ART-experienced patients after M184V (32.0%), T215Y (27.8%), M41L (24.4%), D67N (19.7%), K103N (18.0%), L210W (14.6%), K70R (13.7%), K219QE (11.4%), Y181CIV (9.7%) and G190SA (9.0%). A total of 77% of ART-experienced patients were infected with a subtype B viral strain, 7% with subtype C, 6% with subtype A and 6% with another recognized subtype, whereas 3% had an unclassifiable subtype. There was no evidence of an association between viral subtype and the rate of N348I in either ART-naive or ART-experienced patients (HP et al., data not shown).
Exposure to RTIs and association with N348I mutation
The N348I mutation was observed in viruses from 198 patients (cases) after they started ART. The number of patients for whom the first year of N348I detection To assess the stability of the N348I mutation, we performed a longitudinal analysis on the basis of the 131 cases with one or more resistance tests following the first detection of N348I. The median follow-up was 14 months (interquartile range [IQR] 9-33). An estimated 31% of patients had lost the mutation at 1 year after its detection, increasing to 51% by 2 years and 80% by 5 years (Figure 3) . A more complex analysis (HP et al., data not shown) failed to find any relationship between the loss of the mutation and individual ART drugs received during the relevant interval. The instability of the N348I mutation implies that consideration of treatment exposure shortly prior to the index resistance test, as opposed to lifetime exposure, might provide sharper insights about the drugs that select for N348I. The case-control analysis was therefore repeated, limited to the 2-year period prior to the index resistance test (Table 1) . Findings were broadly consistent with the main analysis, although the effect of zidovudine became stronger and was of borderline significance (P=0.07). Table 2 and Table 3 show analyses of composite variables of exposure to zidovudine and stavudine, and nevirapine and efavirenz. The analysis of any exposure to zidovudine and stavudine was relatively uninformative because virtually all patients had, at some time, received one or both of these drugs. However, in the analysis that considered exposure in the 2 years prior to the resistance test, only 3.1% of cases had no exposure to zidovudine or stavudine compared with 10.5% of controls, which strongly suggested that such exposure Figure 2 . Distribution of the number of RTIs received prior to the index resistance test was associated with a higher risk of N348I. Adjusting for all other drugs, we observed similar estimated ORs in those exposed to zidovudine alone (4.61; P=0.001), to stavudine alone (3.39; P=0.011) or to both drugs (3.15; P=0.023), consistent with the two drugs exerting a similar level of selection pressure for the N348I mutation. The apparent contradictory findings in Table 1 can be explained by the absence of a synergistic effect of exposure to both zidovudine and stavudine along with the small number of patients without exposure to either drug. Analysis of nevirapine and efavirenz as a composite variable showed likewise that their individual effects were underestimated in Table 1 . With the no exposure group as a reference, ORs for exposure to either or both NNRTIs ranged between 2.20 and 2.77.
Association of N348I with classical RT resistance mutations
N348I was rarely observed in isolation; at least one other major RT resistance mutation was detected in 197 (99.5%) of the 198 case samples. In terms of TAMs and NNRTI-associated mutations, 21 (10.6%) samples had neither type of mutation, 49 (24.8%) had TAM(s) alone, 52 (26.0%) had NNRTI mutation(s) alone and 76 (38.4%) had both types of mutation. In summation, 125 (63.1%) samples with N348I coharboured TAM(s), whereas 128 (64.6%) coharboured NNRTI mutation(s). 
Discussion
Consistent with other clinical studies, N348I was highly prevalent in samples from patients experiencing virological failure, although there was evidence of a decrease in more recent years [4] . The decrease might partly reflect changes in antiretroviral prescribing patterns, including an increased use of TDF from 2002 onwards, as well as a shift in clinical indications for performing resistance testing [20] .
In contrast to the body of evidence from in vitro studies, our initial analysis failed to detect an effect of exposure to zidovudine. Because of this unexpected finding, we did an analysis examining the effects of all combinations of exposure to zidovudine and the other thymidine analogue, stavudine. Exposure to both zidovudine and stavudine produced an effect of similar magnitude to exposure to either drug alone, compared with the (very small) group of patients who had received neither drug. This obscured the individual effects of zidovudine and stavudine in the multivariate analysis, lending rationale to the use of a composite exposure variable. Although the role of zidovudine is well documented, in vitro studies have not found that N348I confers reduced susceptibility to stavudine [7, 9] ; however, associations with RNase H mutations (D549N and H539N) have been reported [21] . As our sequences do not extend to the RNase H domain, we were unable to validate these findings. A key finding from our analysis is evidence that the detection of the N348I mutation was much less likely if the patient had received TDF. There are two possible mechanisms, which are not necessarily mutually exclusive, that could explain this finding. First, N348I could render the virus hypersusceptible to TDF, leading to outgrowth of N348I-containing viruses by fitter viral quasispecies under selective drug pressure. The second explanation is that TDF selects for mutations that are antagonistic to N348I at the genomic level; in this case, the use of TDF (and development of the putative mutations) would precede and counter later positive drug selection pressure for N348I. The main mutation selected by TDF is K65R and recent in vitro work has shown antagonism between the effect of K65R and N348I on resistance to NRTIs and NNRTIs (although fold changes for K65R alone were not given) [22] . In addition, that study also showed that K65R reduces viral fitness in the presence of N348I, possibly in a subtype-dependent manner [22] . It should be noted that the K65R mutation is relatively uncommon and, in our study, the mutation was observed in only 5.0% of control patients or 17.4% of controls with prior exposure to TDF. This frequency is too low, even if K65R and N348I never coexisted on the same genome, to entirely account for the strong protective effect of TDF against the development of N348I. In addition, the OR between N348I and exposure to TDF was virtually unchanged if patients with K65R were excluded (HP et al., data not shown). Furthermore, TAMs might add to the complexity of these dynamics because TAMs interact synergistically with N348I in terms of thymidine analogue resistance while being antagonistic (particularly the T125FY mutation) to K65R [23, 24] . There was also weaker evidence of a negative association between exposure to didanosine and N348I; however, one in vitro study suggested N348I conferred resistance to didanosine [7] , although no effect was observed in another study [22] .
Our data suggest that both nevirapine and efavirenz select for N348I. The finding for efavirenz is interesting in the light of previous conflicting evidence, with an association reported in some [6, 8] but not all studies [7, 9] . Although nevirapine and stavudine are no longer preferred options in resource-rich settings, both drugs are often included within first-line regimens in resource-limited settings (through their coformulation in Triomune) [25] . This implies that N348I, and possibly other connection domain mutations, could be highly prevalent within this setting. Theoretically, this could accentuate virological rebound -unrecognized in the absence of routine virological monitoring -with potentially adverse immunological and clinical consequences [26] . By contrast, in resource-rich regions, Atripla (TDF, emtricitabine and efavirenz coformulation) is frequently used as a convenient and effective first-line therapy. Because Atripla contains both efavirenz and TDF, the effect on the development of N348I might be unpredictable, with efavirenz and TDF apparently having counteracting effects.
Yap et al. [6] found that N348I was highly positively associated with many key drug resistance mutations in RT, including M184V, Y181C and TAMs but not K65R; however, these associations might have been an artefact, induced by the inclusion in the analysis of treatment-naive patients, who mostly lack any key mutations, along with treatment-experienced patients [16] . The much weaker associations observed in our analysis is likely caused by having limited the analysis to RTI-experienced patients with at least one major resistance mutation. Nonetheless, some of the findings are difficult to reconcile with those from the analysis of drug exposure. In terms of NNRTI-related mutations, a significant positive association was observed for K103N but not for Y181C, which are the primary mutations selected by efavirenz and nevirapine, respectively [27, 28] . Also, despite the effect of thymidine analogues, no significant relationships were observed for TAMs. Conversely, M184V was strongly linked with N348I, as also noted by Yap et al. [4] , despite inconclusive evidence on whether lamivudine plays a role in the development of N348I. In further analyses to characterize the effect of lamivudine and relationship with M184V, we found that if a patient did not have M184V then exposure to lamivudine was highly protective against the development of N348I and that in those exposed to lamivudine, M184V (found in 55% of controls and 85% of cases) was highly predictive of N348I. This appears to show that M184V was acting as a marker of adherence/drug pressure rather than a biological interaction with N348I.
The discovery of the existence of resistance mutations in the connection and RNase H domains has prompted debate on whether sequencing of routine clinical samples should be extended to include this part of the HIV-1 genome. The argument that the detection of N348I is clinically unimportant because it almost always coexists with other resistance mutations does not seem to us a compelling one. For example, consider a patient whose majority circulating virus harbours K103N and N348I mutations but not TAMs -in this case, knowledge of N348I might be irrelevant to a decision about whether to prescribe nevirapine or efavirenz as K103N confers high-level resistance to both drugs, but it might influence a decision on the use of zidovudine or stavudine. The key issue is whether connection and RNase H domain mutations have a clinically significant adverse effect on therapeutic response, otherwise there is no strong imperative to know of their existence [11, 29] . The identification of individual antiretroviral drugs that select for these mutations does not provide a definitive answer to this question, but should help to focus further research.
